AbCellera Biologics earnings release, August 5, 2026

AbCellera Biologics Inc. (ABCL) · Form 8-K, Item 2.02 · Filed · SEC filing

NEWS RELEASE

AbCellera Reports Q2 2026 Business Results

8/5/2026

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet.”

Q2 2026 Business Summary and Program Updates

● ABCL635 top-line data readout from the Phase 2 trial expected in August 2026.

● ABCL386 and ABCL688 are progressing through IND-enabling activities.

● Announced collaboration with Jazz Pharmaceuticals plc to discover and develop next-generation T-cell engagers (TCEs) for multiple gastrointestinal cancers and other solid tumors. AbCellera is receiving $84 million in total upfront payments, with $56 million for the first two research programs and $28 million for a third program, which will initiate within 12 months. AbCellera is eligible to receive up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments along with tiered royalties on net sales ranging from mid-single digits to low double digits.

● Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026.

● Announced the appointments of Dr. Victor Sandor and Dr. Lynn Seely as independent directors to AbCellera’s board of directors.

● Generated a net loss of $55.4 million, compared to a net loss of $34.7 million in Q2 2025.

● Ended the quarter with over $565 million in total cash balances and marketable securities, providing over $675 million in total available liquidity to execute on AbCellera’s strategy.

Subsequent Event

● On July 29, 2026 announced a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific TCEs for autoimmune diseases and other conditions. AbCellera will receive $28 million in total¹ upfront payments and is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales.

Discussion of Q2 2026 Financial Results

● Revenue – Total revenue was

$4.1 million, compared to $17.1 million in Q2 2025.

● Research & Development (R&D) Expenses – R&D expenses were $46.0 million, compared to $39.2 million in Q2 2025.

● Sales, General, & Administrative (SG&A) Expenses – SG&A expenses were $13.9 million, compared to $22.0 million in Q2 2025.

● Net Loss – Net loss of $55.4 million, or $(0.18) per share on a basic and diluted basis, compared to net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, in Q2 2025.

● Available Liquidity – over $565 million in total cash balances and marketable securities, and $110 million in available non-dilutive government funding, bringing total available liquidity to over $675 million to execute on AbCellera's strategy.

Business Metrics

At the end of Q2 2026, partners led 35 programs that AbCellera believes to be progressing and where AbCellera holds a downstream stake (down from 44 on December 31, 2025). In total, AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on June 30, 2026.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com.

Financial statements

Income Statement

Three months ended June 30, — (Unaudited)

Three months ended June 30, – 2025Three months ended June 30, – 2026Six months ended June 30, – 2025Six months ended June 30, – 2026
Revenue:Research fees6,6393,90110,70712,021
Revenue:Licensing and royalty revenue10,44514910,613341
Revenue:Total revenue17,0844,05021,32012,362
Operating expenses:Research and development(1)39,21345,98781,71192,649
Operating expenses:Sales, general, and administrative(1)21,98613,85041,05426,185
Operating expenses:Depreciation and amortization5,4706,99010,80113,828
Operating expenses:Total operating expenses66,66966,827133,566132,662
Operating expenses:Loss from operations-49,585-62,777-112,246-120,300
Other (income) expense:Interest and other-9,54942-15,073-3,606
Other (income) expense:Grants and incentives-3,692-3,854-7,845-8,193
Other (income) expense:Total other income-13,241-3,812-22,918-11,799
Other (income) expense:Loss before income tax-36,344-58,965-89,328-108,501
Other (income) expense:Income tax recovery-1,617-3,538-8,980-9,909
Other (income) expense:Net loss-34,727-55,427-80,348-98,592
Other (income) expense:Foreign currency translation adjustment4,341-7331,7211,082
Other (income) expense:Comprehensive loss-30,386-56,160-78,627-97,510
Net loss per shareBasic-0.12-0.18-0.27-0.32
Net loss per shareDiluted-0.12-0.18-0.27-0.32
Weighted-average common shares outstandingBasic298,508,601305,557,294298,105,760304,329,623
Weighted-average common shares outstandingDiluted298,508,601305,557,294298,105,760304,329,623

Balance Sheet

December 31, 2025 — (Unaudited)

December 31, 2025June 30, 2026
Current assets:Cash and cash equivalents128,513120,065
Current assets:Marketable securities405,313420,039
Current assets:Total cash, cash equivalents, and marketable securities533,826540,104
Current assets:Accounts and accrued receivable58,29318,597
Current assets:Restricted cash25,00025,000
Current assets:Other current assets111,11395,529
Current assets:Total current assets728,232679,230
Long-term assets:Property and equipment, net428,003416,677
Long-term assets:Intangible assets, net38,38136,530
Long-term assets:Goodwill47,80647,806
Long-term assets:Investments in equity accounted investees62,58065,229
Long-term assets:Other long-term assets51,94862,103
Long-term assets:Total long-term assets628,718628,345
Long-term assets:Total assets1,356,9501,307,575
Current liabilities:Accounts payable and other current liabilities50,78132,484
Current liabilities:Deferred revenue13,52620,705
Current liabilities:Total current liabilities64,30753,189
Long-term liabilities:Operating lease liability137,403129,948
Long-term liabilities:Deferred revenue3,50040,450
Long-term liabilities:Deferred government contributions174,453178,254
Long-term liabilities:Other long-term liabilities10,3839,714
Long-term liabilities:Total long-term liabilities325,739358,366
Long-term liabilities:Total liabilities390,046411,555
Shareholders' equity:Common shares: no par value, unlimited authorized shares at December 31, 2025 and June 30, 2026: 300,600,710 and 306,469,632 shares issued and outstanding at December 31, 2025 and June 30, 2026, respectively802,341821,242
Shareholders' equity:Additional paid-in capital198,279206,004
Shareholders' equity:Accumulated other comprehensive loss-4,234-3,152
Shareholders' equity:Accumulated deficit-29,482-128,074
Shareholders' equity:Total shareholders' equity966,904896,020
Shareholders' equity:Total liabilities and shareholders' equity1,356,9501,307,575

Cash Flow

Six months ended June 30, — (Unaudited)

Six months ended June 30, – 2025Six months ended June 30, – 2026
Cash flows from operating activities:Net loss-80,348-98,592
Cash flows from operating activities:Depreciation of property and equipment8,95111,977
Cash flows from operating activities:Amortization of intangible assets1,8511,851
Cash flows from operating activities:Amortization of operating lease right-of-use assets2,8633,610
Cash flows from operating activities:Stock-based compensation28,99324,299
Cash flows from operating activities:Other707,019
Changes in operating assets and liabilities:Research fees and grants receivable-12,52425,367
Changes in operating assets and liabilities:Income taxes receivable-7,588-8,024
Changes in operating assets and liabilities:Accounts payable and accrued liabilities-7,356-16,621
Changes in operating assets and liabilities:Deferred revenue9,36144,129
Changes in operating assets and liabilities:Deferred grant income-1,681-4,453
Changes in operating assets and liabilities:Other assets13,4501,838
Changes in operating assets and liabilities:Net cash used in operating activities-43,958-7,600
Cash flows from investing activities:Purchases of property and equipment-24,001-5,963
Cash flows from investing activities:Purchase of marketable securities-291,542-308,184
Cash flows from investing activities:Proceeds from marketable securities303,437293,557
Cash flows from investing activities:Receipt of grant funding6,4486,955
Cash flows from investing activities:Long-term investments and other assets-18,218-105
Cash flows from investing activities:Net cash used in investing activities-23,876-13,740
Full release

AbCellera Forward-Looking Statements

This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives² for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.... (truncated)l results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.³

AbCellera Biologics Inc.

Condensed Consolidated Statements of Loss and Comprehensive Loss

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)

(Unaudited)

(1)

Exclusive of depreciation and amortization⁴

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheets

(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)

(Unaudited)⁵

AbCellera Biologics Inc.

Condensed Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars.)

(Unaudited)⁶

Inquiries

Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005

Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · AbCellera Biologics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.